R&D | May 25, 2026
AbbVie signals major oncology momentum at ASCO
With standout ADC and t-cell engager response data across hard-to-treat cancers
With standout ADC and t-cell engager response data across hard-to-treat cancers
The findings support the continued advancement of EB-003, a first-in-class neuroplastogen designed to selectively target both 5-HT2A and 5-HT1B receptors
The decision now moves to the European Commission, with a final ruling expected by the third quarter of 2026
Clearance marks major shift beyond chemotherapy
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
No approved vaccine or specific treatment currently available for Bundibugyo strain Ebola disease
The acquisition marks Anupam Rasayan’s strategic entry into the pharmaceutical formulations segment
Veteran consumer health and FMCG strategist to lead preventive wellness and nutrition portfolio expansion through innovation and modern trade channels
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
Subscribe To Our Newsletter & Stay Updated
